RANKL–RANK signaling in osteoclastogenesis and bone disease
Top Cited Papers
- 1 January 2006
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 12 (1), 17-25
- https://doi.org/10.1016/j.molmed.2005.11.007
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Mechanisms of sex steroid effects on boneBiochemical and Biophysical Research Communications, 2004
- Osteoclast differentiation and activationNature, 2003
- PTEN Regulates RANKL- and Osteopontin-stimulated Signal Transduction during Osteoclast Differentiation and Cell MotilityJournal of Biological Chemistry, 2003
- RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-βNature, 2002
- Receptor Activator of NF-κB Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase Kinase Kinase through a Signaling Complex Containing RANK, TAB2, and TRAF6Molecular and Cellular Biology, 2002
- Male breast cancer in Cowden syndrome patients with germline PTEN mutationsJournal of Medical Genetics, 2001
- Protein Expression and Functional Difference of Membrane-Bound and Soluble Receptor Activator of NF-κB Ligand: Modulation of the Expression by Osteotropic Factors and CytokinesBiochemical and Biophysical Research Communications, 2000
- Activated T Lymphocytes Support Osteoclast Formation in VitroBiochemical and Biophysical Research Communications, 1999
- Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)Journal of Biological Chemistry, 1998
- Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorptionFEBS Letters, 1995